Which HRT Formulation to Ask For: Oral vs. Transdermal vs. Vaginal: A Cardiologist's Read of the Evidence

Most conversations about menopausal hormone therapy stop at the binary: take it or do not take it. The more consequential conversation (which formulation, which delivery route, which progestogen) rarely happens, which means the cardiovascular risk profile a woman ends up with is often a matter of default, not decision.

The Mechanism

To understand why formulation matters, start with what the liver does to oral estrogen.

When estrogen is swallowed as a tablet or capsule, it is absorbed from the gastrointestinal tract and enters the portal circulation, which routes it directly through the liver before it reaches systemic blood. This hepatic first-pass metabolism is not passive transit. The liver sees a large concentration of estrogen and responds by upregulating the production of several proteins that are directly relevant to cardiovascular and clotting risk.

What oral estrogen does in the liver:

• Increases production of clotting factors VII, VIII, and fibrinogen, while reducing levels of protein S (a natural anticoagulant)
• Increases production of C-reactive protein, an inflammatory marker associated with cardiovascular risk
• Upregulates hepatic VLDL synthesis, raising circulating triglycerides
• Elevates sex hormone binding globulin (SHBG), which binds free testosterone and affects libido and energy

The net effect is a prothrombotic, pro-inflammatory hepatic signal that does not occur when estrogen is delivered transdermally. This is not a subtle pharmacokinetic distinction; it is the mechanism that produces the VTE (venous thromboembolism) risk difference between oral and transdermal estrogen delivery.

Transdermal estrogen, absorbed through the skin directly into capillaries and then systemic circulation, bypasses the liver on first pass entirely. The liver sees only the same circulating estradiol concentrations as every other tissue. It does not receive the concentrated portal load that triggers clotting factor upregulation. The consequence is a clotting factor and VTE risk profile that observational evidence shows is meaningfully safer.

This difference applies to all oral estrogen, but it is compounded by the specific compound used. Oral 17beta-estradiol (Estrace, generic estradiol) is bioidentical to the estrogen the ovary produces. Conjugated equine estrogen (CEE, brand name Premarin) is derived from pregnant mare urine and contains a mixture of estrogen compounds, predominantly estrone sulfate and equilin sulfate, rather than pure 17beta-estradiol. CEE is structurally distinct from human estrogen, is not bioidentical, and produces more potent hepatic effects than oral 17beta-estradiol: greater elevation of clotting factors, higher triglycerides, and higher SHBG for equivalent systemic estrogenic effect. The Women’s Health Initiative used oral CEE at 0.625mg daily. Its findings cannot be extrapolated to transdermal 17beta-estradiol, which is a different molecule delivered by a different route.

The progestogen side of the equation

Women with an intact uterus require a progestogen component alongside estrogen to prevent endometrial hyperplasia and cancer from unopposed estrogen stimulation. The choice of progestogen has independent effects on cardiovascular and metabolic risk.

Medroxyprogesterone acetate (MPA, brand name Provera) is the synthetic progestin used in the WHI combined arm. It is not identical to natural progesterone; it is a synthetic derivative that retains progesterone receptor binding but adds androgenic activity through partial androgen receptor binding. That androgenic activity has metabolic consequences: MPA raises LDL cholesterol, lowers HDL cholesterol, increases insulin resistance, and partially opposes the beneficial endothelial and lipid effects of co-administered estrogen. The WHI combination of oral CEE plus MPA produced a formulation where the oral route added VTE risk and the MPA component worked against several of estrogen’s favorable vascular effects.

Micronized progesterone (brand names Prometrium in the US, Utrogestan in Europe) is bioidentical progesterone: the same molecule the ovary produces, processed to microscopic particle size to allow oral absorption. It has no androgenic activity, does not adversely affect the lipid profile, and does not oppose estrogen’s endothelial effects to the same degree that MPA does. It also has sedative properties through conversion to allopregnanolone, a neurosteroid that modulates GABA receptors, making it useful for the sleep disruption common in perimenopause.

Dydrogesterone (available in Europe and some other markets, less available in the US) is a synthetic progestin with no androgenic activity and a more favorable metabolic profile than MPA, though less-studied overall than micronized progesterone.

The levonorgestrel intrauterine device (Mirena, Liletta) used alongside systemic transdermal estrogen is a different approach: the IUD delivers levonorgestrel locally to the uterine lining, where it provides endometrial protection, while systemic progestogen exposure remains minimal. Levonorgestrel has androgenic properties when given systemically, but the local IUD delivery minimizes those systemic effects. For women who cannot tolerate oral micronized progesterone (due to the sedating effect), a levonorgestrel IUD paired with transdermal estrogen is a reasonable alternative that keeps systemic progestogen exposure low.

What the Evidence Shows

The distinction between oral and transdermal estrogen in VTE risk is one of the best-documented pharmacological risk differences in MHT literature, though it comes primarily from observational data rather than randomized trials designed for this comparison.

ESTHER study (France, 2003-2007)

The ESTHER (Etude Epidemiologique de Femmes de la Mutuelle Generale de l’Education Nationale) case-control study enrolled 271 women with confirmed VTE and 610 matched controls. Oral estrogen use was associated with an odds ratio of 4.2 for VTE compared with non-users. 4 / Promising Transdermal estrogen use showed no significant VTE elevation: odds ratio 0.9 (95% CI 0.45 to 1.8), statistically indistinguishable from non-use. The study also found that the addition of micronized progesterone or dydrogesterone to transdermal estrogen did not increase VTE risk, while the addition of synthetic progestins (norpregnane derivatives) did. This is a case-control design with inherent limitations, but the magnitude and consistency of the oral-versus-transdermal difference is clinically striking.

Million Women Study (UK, 2003)

This large prospective cohort of over one million postmenopausal women found elevated VTE risk with oral MHT compared with no MHT. 4 / Promising The relative risk for VTE with oral combined MHT was approximately 2.1. Transdermal-only users showed a substantially lower risk elevation. The Million Women Study was observational and subject to healthy user bias and confounding by indication, but its results were directionally consistent with ESTHER and with the biological mechanism of first-pass hepatic effects.

E3N cohort (France)

The E3N (Etude Epidemiologique aupres de femmes de la Mutuelle Generale de l’Education Nationale) cohort followed 98,997 French women from 1990 onward. Because French MHT prescribing patterns favor transdermal estrogen and micronized progesterone more than US and UK patterns, the E3N cohort provided population-level data on the transdermal plus micronized progesterone combination. 4 / Promising

The E3N data on breast cancer risk showed that estrogen combined with micronized progesterone did not significantly increase breast cancer risk (relative risk 1.00, 95% CI 0.83 to 1.22), while estrogen combined with synthetic progestins produced a statistically significant excess (relative risk 1.69, 95% CI 1.50 to 1.91). For cardiovascular purposes, E3N data also supported the favorable metabolic and lipid neutrality of the micronized progesterone combination versus synthetic progestin combinations.

Women’s Health Initiative (WHI, 2002)

The WHI randomized controlled trial enrolled 16,608 women aged 50 to 79 (mean age 63.3 years) with an intact uterus to oral CEE 0.625mg plus MPA 2.5mg daily versus placebo. The combined trial was stopped early in 2002 after a mean follow-up of 5.2 years. 5 / Solid

The WHI found increased VTE risk (hazard ratio 2.06), increased breast cancer risk after five years, increased stroke, and no overall cardiovascular benefit in this population that was on average 13 years past menopause at enrollment. The WHI findings are important and real for the formulation and population studied. They are not directly applicable to transdermal 17beta-estradiol plus micronized progesterone, or to women who initiate MHT within 10 years of menopause.

ELITE trial (Early vs. Late Intervention Trial with Estradiol)

The ELITE trial randomized 643 healthy postmenopausal women to oral 17beta-estradiol 1mg daily plus vaginal progesterone gel versus placebo, stratified by time since menopause: early (less than 6 years since menopause) or late (more than 10 years). 4 / Promising The primary outcome was carotid intima-media thickness (CIMT), a marker of subclinical atherosclerosis.

In the early menopause group, women randomized to estradiol showed significantly slower CIMT progression compared with placebo (0.0044mm/year slower, p = 0.008). In the late menopause group, there was no significant difference between estradiol and placebo. ELITE is the highest-quality trial evidence for the “timing hypothesis” in MHT: early initiation after menopause shows cardiovascular protection; late initiation in established atherosclerosis does not, and may worsen outcomes. ELITE used oral 17beta-estradiol, not transdermal, and vaginal progesterone gel rather than oral micronized progesterone, so the formulation is not identical to the transdermal-plus-oral-progesterone combination, but the timing principle the trial established is directly relevant to the formulation discussion.

Danish Osteoporosis Prevention Study (DOPS)

DOPS randomized 1,006 recently postmenopausal Danish women to a hormone regimen or no treatment and followed them for up to 16 years. Women randomized to hormone therapy had significantly lower rates of the composite outcome of mortality, heart attack, and heart failure (hazard ratio 0.52, 95% CI 0.29 to 0.93). 4 / Promising This is a trial in recently postmenopausal women (consistent with the timing hypothesis) using a different formulation from the WHI. DOPS used sequential estradiol with progestin cycles rather than the fixed-dose CEE plus MPA combination of the WHI.

The picture across these studies is consistent: formulation and timing are not secondary considerations. They are the variables that explain most of the apparent contradiction between early trials suggesting cardiovascular benefit from MHT and the WHI results suggesting harm.

What to Do This Week

1. Ask specifically what formulation is being prescribed. When your physician recommends MHT, ask: “Is this transdermal estradiol or oral estrogen? Is the progestogen micronized progesterone (Prometrium) or a synthetic progestin like medroxyprogesterone acetate?” These are not esoteric questions. They are the two variables that determine the cardiovascular and thrombotic risk profile of the regimen.

2. If you have VTE history or thrombophilia, make that explicit. Tell your prescribing physician: “I have a personal history of DVT” or “I was told I carry Factor V Leiden.” Request transdermal delivery specifically and ask whether the formulation choice accounts for your clotting history. Oral estrogen’s fourfold VTE odds ratio versus the neutral transdermal odds ratio from ESTHER means this is not a distinction to skip.

3. Request transdermal 17beta-estradiol by name if you are a candidate for systemic MHT. Available formulations include Vivelle-Dot (patch, changed twice weekly), Climara (patch, changed weekly), Alora (patch, changed twice weekly), EstroGel (gel, applied daily to arm or shoulder), Divigel (gel sachet, applied daily), and Evamist (spray, applied to forearm). These are FDA-approved, insurance-covered formulations, not compounded alternatives. You are not asking for something outside the standard of care; you are asking for the formulation the evidence supports.

4. If your physician recommends a progestogen, ask whether Prometrium (micronized progesterone) is appropriate. The standard doses are 100mg nightly for continuous regimens or 200mg for the first 12 days of each calendar month in sequential regimens. If you cannot tolerate the sedating effect, ask about the levonorgestrel IUD (Mirena) as an alternative for uterine protection while continuing transdermal estradiol.

5. Ask about vaginal estrogen separately if you have genitourinary symptoms. Vaginal dryness, painful intercourse, and recurrent UTIs related to genitourinary syndrome of menopause can be treated with low-dose local vaginal estrogen (Vagifem 10mcg tablets, Imvexxy inserts, or Estring vaginal ring) without systemic hormone exposure. This is a distinct treatment from systemic MHT, does not carry cardiovascular or VTE risk, and is appropriate for many women who are not candidates for or do not want systemic hormones, including women with hormone-receptor-positive breast cancer in many cases. These two questions, whether you want treatment for systemic menopause symptoms and whether you want treatment for genitourinary symptoms, can have different answers.

Vaginal Estrogen: A Distinct Category

Low-dose vaginal estrogen sits outside the systemic MHT discussion entirely and deserves to be understood on its own terms.

Genitourinary syndrome of menopause (GSM) affects approximately 50 to 70 percent of postmenopausal women and includes vaginal dryness, vaginal atrophy, painful intercourse, urinary urgency, and recurrent urinary tract infections. These symptoms result from estrogen deficiency in genitourinary tissues and do not reliably respond to lubricants or moisturizers for the structural changes underlying them.

Low-dose vaginal estrogen delivers 17beta-estradiol or conjugated estrogens directly to vaginal tissue in doses calibrated to treat local atrophy without raising systemic estradiol levels above the postmenopausal range. The available options include Vagifem (estradiol vaginal tablets 10mcg, inserted twice weekly after an initial daily loading period), Imvexxy (estradiol vaginal inserts 4mcg or 10mcg), Estring (estradiol vaginal ring releasing approximately 7.5mcg per day over 90 days), and Premarin vaginal cream (conjugated estrogens, which has higher systemic absorption than the tablet or ring formulations and requires careful dosing). 5 / Solid

At these doses, serum estradiol remains in the postmenopausal range. The cardiovascular risk discussion applicable to systemic MHT does not apply. Vaginal estrogen does not raise clotting factors. It does not elevate VTE risk. It does not produce systemic estrogenic effects on the breast. The American College of Obstetricians and Gynecologists and the American Cancer Society both recognize low-dose vaginal estrogen as appropriate for most breast cancer survivors experiencing GSM, including those on aromatase inhibitors, though this should be discussed with the treating oncologist.

For women who are otherwise excellent candidates for systemic MHT, vaginal estrogen is not a substitute for the systemic benefits, including bone density maintenance, vasomotor symptom relief, and potentially cardiovascular protection in the window immediately after menopause. It is a supplement or, for women who cannot use systemic hormones, a safer treatment for the specific local problem of genitourinary atrophy.

The formulation decision for vaginal estrogen also matters at the margins. The 10mcg vaginal tablet (Vagifem) and the vaginal ring (Estring) produce less systemic absorption than vaginal cream at equivalent clinical doses. For women where minimizing any systemic estrogen exposure is a priority, the tablet or ring is preferred over cream.

Related Reading

For the full cardiovascular decision around MHT: The MHT Decision Is a Cardiac Decision.

For the compounded HRT question: Compounded HRT vs. FDA-Approved HRT.

For the estrogen biology that explains why formulation matters: Estrogen Is Not Just a Reproductive Hormone.